• Kim MG*, Kim M, Kim JH, Kim K. Fine-Tuning BERT Models to Classify Misinformation on Garlic and COVID-19 on Twitter. Int J Environ Res Public Health. 2022;19(9):5126.

  • Kim J, Kim MG*, Lim KM*. Participation in and withdrawal from cancer clinical trials: A survey of clinical research coordinators. Asia Pac J Oncol Nurs. 2022;9(4):197-201.

  • Yang BR, Lee JY, Kim MG*. The risk of pulmonary adverse drug reactions of rebamipide and other drugs for acid-related diseases: An analysis of the national pharmacovigilance database in South Korea. J Dig Dis. 2022 Feb;23(2):118-123. doi: 10.1111/1751-2980.13075.

  • Kim B, Jang YJ, Cho HR, Kim SY, Jeong JE, Shim MK, Kim MG*. Predicting completion of clinical trials in pregnant women: Cox proportional hazard and neural network models. Clin Transl Sci. 2022 Mar;15(3):691-699. doi: 10.1111/cts.13187.


  • Moon SM, Joo MJ, Lee YS, Kim MG*. Effects of Coffee Consumption on Insulin Resistance and Sensitivity: A Meta-Analysis. Nutrients 2021, 13(11), 3976;

  • Song G, Yoon HY, Yee J, Kim MG, Gwak HS*. Antihypertensive drug use and psoriasis: A systematic review, meta- and network meta-analysis. Br J Clin Pharmacol. 2021 Oct 5. doi: 10.1111/bcp.15060.

  • Lee JY, Lee YS, Kim DH, Lee HS, Yang BR, Kim MG*. The Use of Social Media in Detecting Drug Safety-Related New Black Box Warnings, Labeling Changes, or Withdrawals: Scoping Review. JMIR Public Health Surveill. 2021 Jun 28;7(6):e30137.

  • Choi JY, Choi JH, Kim MG*, Rhie SJ*. Signal Detection of Adverse Drug Reactions of Cephalosporins Using Data from a National Pharmacovigilance Database. Pharmaceuticals (Basel). 2021 May 2;14(5):425.

  • Park S, Choi YJ, Kang JE, Kim MG, Jung Geum M, Kim SD, Rhie SJ*. P2Y12 Antiplatelet Choice for Patients with Chronic Kidney Disease and Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. J Pers Med. 2021 Mar 21;11(3):222.

  • Lee Y, Park J, Min M, Lee Y, Yu Y, Shim MK, Kim MG*. Gender Equity and Vertically Transmitted Infections: A Country-Level Analysis Across 153 Countries. Health Equity. 2021 Jan 25;5(1):23-29.


  • Kim MG*, Yang I, Lee HS, Lee JY, Kim K. Lipid-modifying effects of krill oil vs fish oil: a network meta-analysis. Nutr Rev. 2020 Sep 1;78(9):699-708.

  • Kim MG*, Kim J, Kim SC, Jeong J. Twitter Analysis of the Nonmedical Use and Side Effects of Methylphenidate: Machine Learning Study. J Med Internet Res. 2020 Feb 24;22(2):e16466.

  • Lee HS, Lee JJ, Kim MG, Kim KT, Cho CW, Kim DD, Lee JY*. Sprinkle Formulations—A Review of Commercially Available Products. Asian J Pharm Sci. 2020 May;15(3):292-310.

  • Lee NE, Kim MG, Sohn HS*. Gap between patient expectation and perception during pharmacist-patient communication at community pharmacy. Int J Clin Pharm. 2020 Apr;42(2):677-684.

  • Kim DH, Lee HS, Kwon TW, Han YM, Kang NW, Lee MY, Kim DD, Kim MG*, Lee JY*. Single enzyme nanoparticle, an effective tool for enzyme replacement therapy. Arch Pharm Res. 2020 Jan;43(1):1-21.

  • Kim JJ, Kim MG, Park SC, Hwang J, Sohn HS*. Real-world prescribing and switching patterns of non-calcium containing phosphate binders in dialysis patients in South Korea. Int J Clin Pharmacol Ther. 2020 Mar;58(3):166-173.


  • Kim MG, Huh S, Han N, Kim JH, Kim K, Lee E, Kim IW, Oh JM. Analysis of Issues and Future Trends Impacting Drug Safety in South Korea. Int J Environ Res Public Health. 2019 Sep 12;16(18). pii: E3368.

  • Kwon KE, Kim MG, Shim MK, Sohn HS*. The Status and Perception on Compounding Powdered Medicine for Adult Patients in Community Pharmacies. Yakhak Hoeji. 2019;63(4):185-191.

  • Kim JH, Han N, Kim MG, Kim YW, Jang H, Yun HY, Yu MY, Kim IW, Kim YS, Oh JM*. Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients. Sci Rep. 2019 Aug 13;9(1):11740.

  • Jang EJ, Ha JE, Im SG, Kim MG, Sohn HS*. A Real-World Analysis of Prescribing Patterns and Non-persistence of Anti-TNFα Therapy for Inflammatory Bowel Disease. Clin Drug Investig. 2019 Jul;39(7):625-630.

  • Kim K, Kwak A, Choi CU, Kim JH, Kim MG, Oh JM, Ji E. Differences in preventing new-onset cardiovascular events with statin therapy in seniors aged 75 years and over: A cohort study in the South Korean National Health Insurance Database. Basic Clin Pharmacol Toxicol. 2019 Aug;125(2):108-116.

  • Kim IW, Jang H, Kim JH, Kim MG, Kim S, Oh JM*. Computational Drug Repositioning for Gastric Cancer using Reversal Gene Expression Profiles. Sci Rep. 2019 Feb 25;9(1):2660.

  • Kim SC, Kim MG*. A meta-analysis of the influence of UGT1A6 genetic polymorphisms on valproic acid pharmacokinetics. Int J Clin Pharmacol Ther. 2019 Mar;57(3):144-151.

  • Kim Y, Lee YS, Kim MG, Song YK, Kim Y, Jang H, Kim JH, Han N, Ji E, Kim IW, Oh JM*. The effect of selective serotonin reuptake inhibitors on major adverse cardiovascular events: a meta-analysis of randomized-controlled studies in depression. Int Clin Psychopharmacol. 2019 Jan;34(1):9-17.


  • Sohn M, Kim MG, Han N, Kim IW, Gim J, Min SI, Song EY, Kim YS, Jung HS, Shin YK, Ha J, Oh JM*. Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients. Sci Rep. 2018 Dec 24;8(1):18064.

  • Kim MG, Kwak A, Choi B, Ji E, Oh JM, Kim K*. Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: A meta-analysis. Basic Clin Pharmacol Toxicol. 2019 Jun;124(6):691-703.

  • Kim SC, Kim MG*. Meta-analysis of the Influence of UGT Genetic Polymorphisms on Lamotrigine Concentration. Basic Clin Pharmacol Toxicol. 2019 Feb;124(2):163-169.

  • Ji E, Kim MG, Oh JM*. CYP3A5 Genotype Based Model to Predict Tacrolimus Dosage in the Early Postoperative Period after Living Donor Liver Transplantation. Ther Clin Risk Manag. 2018 Oct 25;14:2119-2126.

  • Song YK, Kim JH, Choi B, Han N, Kim MG, Lee J, Lee H, Yoon J, Lee BJ, Oh JM*. Strategic Priorities to Improve Effectiveness of Anti-smoking Interventions for the Korean Military: An Application of the Analytic Hierarchy Process. Mil Med. 2018 Jul 1;183(7-8):e223-e230.

  • Kim MG, Jeong CR, Kim HJ, Kim JH, Song YK, Kim KI, Ji E, Yoon SS, Koh Y, Cho YS, Kim IW, Oh JM*. Network analysis of drug-related problems in hospitalized patients with hematologic malignancies. Support Care Cancer. 2018 Aug;26(8):2737-2742.

  • Jang HY, Song YK, Kim JH, Kim MG, Han N, Lee HY, Kim IW, Oh JM*. Impact of depression on change in coronary heart disease risk status: the Korean Genome and Epidemiology Study (KoGES). Ther Clin Risk Manag. 2018 Jan 10;14:121-128.

  • Kim JH, Han N, Kim MG, Yun HY, Lee S, Bae E, Kim YS, Kim IW, Oh JM*. Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers. Sci Rep. 2018 Jan 26;8(1):1687.


  • Han N, Han SH, Song YK, Kim MG, Kim YS, Kim IW, Oh JM*. Statin therapy for preventing cardiovascular diseases in patients treated with tacrolimus after kidney transplantation. Ther Clin Risk Manag. 2017 Nov 21;13:1513-1520.

  • Song YK, Han N, Kim MG, Chang HJ, Sohn HS, Ji E, Oh JM*. A national pharmacoepidemiological study of antibiotic use in Korean paediatric outpatients. Arch Dis Child. 2017 Jul;102(7):660-666.

  • Kim JW, Kim MG, Lee HJ, Koh Y, Kwon JH, Kim I, Park S, Kim BK, Oh JM, Kim KI, Yoon SS*. Topical Recombinant Human Epidermal Growth Factor for Oral Mucositis Induced by Intensive Chemotherapy with Hematopoietic Stem Cell Transplantation: Final Analysis of a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial. PLoS One. 2017 Jan 3;12(1):e0168854.

  • Kim MG, Ko M, Kim IW, Oh JM*. Meta-analysis of the impact of thioprine S-methyltransferase polymorphisms on the tolerable 6-mercaptopurine dose considering initial dose and ethnic difference. Onco Targets Ther. 2016 Nov 18;9:7133-7139.

  • Jeong S, Kim JH, Kim MG, Han N, Kim IW, Kim T, Oh JM*. Genetic polymorphisms of CASR and cancer risk: evidence from meta-analysis and HuGE review. Onco Targets Ther. 2016 Feb 9;9:655-69.

  • Choi B, Kim MG, Han N, Kim T, Ji E, Park S, Kim IW, Oh JM*. Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation. Pharmacogenomics. 2015;16(14):1585-94.

  • Kim MG, Kim IW, Choi B, Han N, Yun HY, Park S, Oh JM*. Population pharmacokinetics of cyclosporine in hematopoietic stem cell transplant patients: consideration of genetic polymorphisms. Ann Pharmacother. 2015 Jun;49(6):622-30.

  • Kim MG, Han N, Lee EK, Kim T*. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis. Bone Marrow Transplant. 2015 Apr;50(4):523-30.

  • Cho IH, Song YK, Kim MG, Han N, Kim T, Oh JM. Association between interleukin-10 promoter gene polymorphisms and acute graft-versus-host disease after hematopoietic stem cell transplantation: A systematic review and meta-analysis. Hematology. 2015 Apr;20(3):121-8.

  • Kim IW, Han N, Kim MG, Kim T, Oh JM. Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using The Cancer Genome Atlas data. Pharmacogenet Genomics. 2015 Jan;25(1):1-7.

  • Han N, Ha S, Yun HY, Kim MG, Min SI, Ha J, Lee JI, Oh JM, Kim IW. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. Basic Clin Pharmacol Toxicol. 2014 May;114(5):400-6.

  • Kim IW, Yun HY, Choi B, Han N, Kim MG, Park S, Oh JM. Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation. Eur J Clin Pharmacol. 2013 Aug;69(8):1543-51.

  • Song J, Kim MG, Choi B, Han NY, Yun HY, Yoon JH, Oh JM. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics. Ann Pharmacother. 2012 Sep;46(9):1141-51.